[ Title ]
- Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
[ Journal ]
- JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
[ Author ]
- Weidanz, JA Doll, KL Mohana-Sundaram, S Wichner, T Lowe, DB Gimlin, S Weidanz, DW Magnusson, R Hawkins, OE
[ Abstract ]
- According to the American Cancer Society, more than 200,000 women will
be diagnosed with invasive breast cancer each year and approximately
40,000 will die from the disease. The human leukocyte antigen (HLA)
class I samples peptides derived from proteasomal degradation of
cellular proteins and presents these fragments on the cell surface for
interrogation by circulating cytotoxic T lymphocytes (CTL). Generation
of T-cell receptor mimic (TCRm) monoclonal antibodies (mAbs) which
recognize breast cancer specific peptide/HLA-A(star)02: 01 complexes
such as those derived from macrophage migration inhibitory factor
(MIF19-27) and NY-ESO-1(157-165) enable detection and destruction of
breast cancer cells in the absence of an effective anti-tumor CTL
response. Intact class I HLA/peptide complexes are shed by breast cancer
cells and represent potentially relevant cancer biomarkers. In this
work, a breakthrough biomarker screening system for cancer diagnostics
incorporating T-cell receptor mimic monoclonal antibodies combined with
a novel, label-free biosensor utilizing guided-mode resonance (GMR)
sensor technology is presented. Detection of shed MIF/HLA-A(star)02: 01
complexes in MDA-MB-231 cell supernatants, spiked human serum, and
patient plasma is demonstrated. The impact of this work could
revolutionize personalized medicine through development of companion
disease diagnostics for targeted immunotherapies.
[ URL ]
- http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=Alerting&SrcApp=Alerting&DestApp=WOS&DestLinkType=FullRecord;UT=WOS:000361534300005